Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1947 2
1948 2
1949 5
1950 4
1952 2
1953 1
1954 1
1956 2
1957 2
1958 4
1959 2
1960 3
1961 3
1962 3
1964 2
1965 1
1967 6
1968 3
1969 6
1970 3
1971 3
1972 4
1973 3
1975 3
1976 10
1977 3
1978 2
1979 6
1980 7
1981 4
1982 4
1983 11
1984 12
1985 12
1986 17
1987 17
1988 36
1989 22
1990 30
1991 35
1992 32
1993 30
1994 30
1995 34
1996 13
1997 26
1998 25
1999 25
2000 22
2001 25
2002 32
2003 24
2004 21
2005 38
2006 34
2007 40
2008 38
2009 41
2010 49
2011 51
2012 57
2013 56
2014 35
2015 41
2016 57
2017 61
2018 42
2019 44
2020 49
2021 47
2022 30
Text availability
Article attribute
Article type
Publication date

Search Results

1,335 results
Results by year
Filters applied: . Clear all
Page 1
A decade of clinical development of PARP inhibitors in perspective.
Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS. Mateo J, et al. Among authors: kaye sb. Ann Oncol. 2019 Sep 1;30(9):1437-1447. doi: 10.1093/annonc/mdz192. Ann Oncol. 2019. PMID: 31218365 Free PMC article. Review.
Pseudomonas aeruginosa and microbial keratitis.
Hilliam Y, Kaye S, Winstanley C. Hilliam Y, et al. Among authors: kaye s. J Med Microbiol. 2020 Jan;69(1):3-13. doi: 10.1099/jmm.0.001110. J Med Microbiol. 2020. PMID: 31750813 Review.
BMJ Open Ophthalmology.
Kaye SB. Kaye SB. BMJ Open Ophthalmol. 2020 Sep 1;5(1):e000530. doi: 10.1136/bmjophth-2020-000530. eCollection 2020. BMJ Open Ophthalmol. 2020. PMID: 32923680 Free PMC article. No abstract available.
Reply.
Steger B, Romano V, Kaye SB. Steger B, et al. Among authors: kaye sb. Cornea. 2016 Mar;35(3):e8. doi: 10.1097/ICO.0000000000000749. Cornea. 2016. PMID: 26840597 No abstract available.
DSAEK and STC-6 Needle.
Gadhvi KA, Pagano L, Menassa N, Borroni D, Kaye SB, Levis HJ, Romano V. Gadhvi KA, et al. Among authors: kaye sb. Cornea. 2021 Mar 1;40(3):e5. doi: 10.1097/ICO.0000000000002600. Cornea. 2021. PMID: 33273191 No abstract available.
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.
de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA. de Bono J, et al. Among authors: kaye s. Cancer Discov. 2017 Jun;7(6):620-629. doi: 10.1158/2159-8290.CD-16-1250. Epub 2017 Feb 27. Cancer Discov. 2017. PMID: 28242752 Free PMC article. Clinical Trial.
Expanding the supply of donor grafts.
Gadhvi KA, Coco G, Pagano L, Kaye SB, Ferrari S, Levis HJ, Parekh M, Romano V. Gadhvi KA, et al. Among authors: kaye sb. Cornea. 2021 Sep 1;40(9):e16-e17. doi: 10.1097/ICO.0000000000002777. Cornea. 2021. PMID: 34050068 No abstract available.
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM. Sandhu SK, et al. Among authors: kaye sb. Lancet Oncol. 2013 Aug;14(9):882-92. doi: 10.1016/S1470-2045(13)70240-7. Epub 2013 Jun 28. Lancet Oncol. 2013. PMID: 23810788 Clinical Trial.
1,335 results